What top creators are saying about Summit Therapeutics(SMMT)
Biopharmaceutical company
5 AI-extracted insights from 4 sources — podcasts, YouTube channels, and X/Twitter accounts.
Creator sentiment — last 30 days
Not enough scored insights about Summit Therapeutics in the last 30 days yet.
Top creators covering Summit Therapeutics (SMMT)
The 4 sources with the most insights about Summit Therapeutics on Kazuha.
Latest insights about Summit Therapeutics (SMMT)
AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.
Wednesday, September 30, 2026
The stock rose about 21% after AstraZeneca announced a $2 billion investment and partnership. The speaker saw potential value in combination trials but questioned how much value the investment alone added.
Tuesday, September 29, 2026
The host viewed AstraZeneca's $2 billion investment and partnership as potentially useful for collaboration and combination trials, but said the investment alone did not prove commercial success and the stock could give back gains.
Wednesday, December 31, 2025
Mentioned as a liked small-cap biotech name that could be an M&A target, potentially leading to sharp stock price increases.
Monday, October 27, 2025
A contrarian bullish opportunity; the market may be overly skeptical of the Chinese data for its drug Ivonescamab. It is a high-risk, high-reward play that could be significantly undervalued if the drug is successful.
Monday, September 15, 2025
Considered a very compelling bullish signal due to two co-CEOs each purchasing $6 million in stock after a recent price drop, with one insider having a strong track record.
Wednesday, September 30, 2026
The stock rose about 21% after AstraZeneca announced a $2 billion investment and partnership. The speaker saw potential value in combination trials but questioned how much value the investment alone added.
Tuesday, September 29, 2026
The host viewed AstraZeneca's $2 billion investment and partnership as potentially useful for collaboration and combination trials, but said the investment alone did not prove commercial success and the stock could give back gains.
Wednesday, December 31, 2025
Mentioned as a liked small-cap biotech name that could be an M&A target, potentially leading to sharp stock price increases.
Monday, October 27, 2025
A contrarian bullish opportunity; the market may be overly skeptical of the Chinese data for its drug Ivonescamab. It is a high-risk, high-reward play that could be significantly undervalued if the drug is successful.
Monday, September 15, 2025
Considered a very compelling bullish signal due to two co-CEOs each purchasing $6 million in stock after a recent price drop, with one insider having a strong track record.
Discussed alongside Summit Therapeutics (SMMT)
Other assets that creators frequently mention in the same content as Summit Therapeutics.
Frequently asked
Which podcasters and creators cover Summit Therapeutics (SMMT) the most?
The most active sources covering Summit Therapeutics (SMMT) on Kazuha are @realmartinshkreli, @ceowatcher, @theshkrelipill, RiskReversal Media. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.
How many insights about Summit Therapeutics (SMMT) are on Kazuha?
Kazuha has indexed 5 AI-extracted insights about Summit Therapeutics (SMMT) from 4 different sources. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.
What other assets do creators discuss alongside Summit Therapeutics (SMMT)?
Creators covering Summit Therapeutics (SMMT) most frequently also discuss MRK, NVDA, AVGO, LLY, INTC. See the "Discussed alongside" section above for full asset pages.